Szanowni Państwo, w związku z bardzo dużą ilością zgłoszeń, rejestracją danych w dwóch systemach bibliograficznych, a jednocześnie zmniejszonym zespołem redakcyjnym proces rejestracji i redakcji opisów publikacji jest wydłużony. Bardzo przepraszamy za wszelkie niedogodności i dziękujemy za Państwa wyrozumiałość.
Repository logoRepository logoRepository logoRepository logo
Repository logoRepository logoRepository logoRepository logo
  • Communities & Collections
  • Research Outputs
  • Employees
  • AAAHigh contrastHigh contrast
    EN PL
    • Log In
      Have you forgotten your password?
AAAHigh contrastHigh contrast
EN PL
  • Log In
    Have you forgotten your password?
  1. Home
  2. Bibliografia UPP
  3. Bibliografia UPP
  4. Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
 
Full item page
Options

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy

Type
Journal article
Language
English
Date issued
2023
Author
Tomela, Katarzyna
Pietrzak, Bernadeta 
Galus, Łukasz
Mackiewicz, Jacek
Schmidt, Marcin 
Mackiewicz, Andrzej Adam
Kaczmarek, Mariusz
Faculty
Wydział Nauk o Żywności i Żywieniu
Journal
Cells
DOI
10.3390/cells12050789
Web address
https://www.mdpi.com/2073-4409/12/5/789
Volume
12
Number
5
Pages from-to
art. 789
Abstract (EN)
Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 advanced melanoma patients were analysed before the first administration of anti-PD-1 immunotherapy and in the third month of treatment for MDSC, immature monocytic (ImMC), monocytic MDSC (MoMDSC) and granulocytic MDSC (GrMDSC) by multi-channel flow cytometry. Cell frequencies were correlated with response to immunotherapy, progression-free survival (PFS) and lactate dehydrogenase (LDH) serum level. Responders to anti-PD-1 therapy had higher MoMDSC levels (4.1 ± 1.2%) compared to non-responders (3.0 ± 1.2%) (p = 0.0333) before the first administration of anti-PD-1. No significant changes in MDSCs frequencies were observed in the groups of patients before and in the third month of therapy. The cut-off values of MDSCs, MoMDSCs, GrMDSCs and ImMCs for favourable 2- and 3-year PFS were established. Elevated LDH level is a negative prognostic factor of response to the treatment and is related to an elevated ratio of GrMDSCs and ImMCs level compared to patients’ LDH level below the cut-off. Our data may provide a new perspective for more careful consideration of MDSCs, and specially MoMDSCs, as a tool for monitoring the immune status of melanoma patients. Changes in MDSC levels may have a potential prognostic value, however a correlation with other parameters must be established.
Keywords (EN)
  • melanoma

  • immunotherapy

  • anty-PD-1

  • MDSC

License
cc-bycc-by CC-BY - Attribution
Open access date
March 2, 2023
Fundusze Europejskie
  • About repository
  • Contact
  • Privacy policy
  • Cookies

Copyright 2025 Uniwersytet Przyrodniczy w Poznaniu

DSpace Software provided by PCG Academia